Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 5Urogenital Neoplasms 1Prostatic Diseases 1Metastatic Neuroendocrine Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Advanced Gastroenteropancreatic Neuroendocrine Tumor 1

Interventions

pembrolizumab 3fludarabine 3aldesleukin 3Cyclophosphamide 3cabozantinib 2Specimen Handling 2Nivolumab 2Magnetic Resonance Spectroscopy 2Ipilimumab 2CTLA-4 Antigen 2olaparib 1gallium 68 PSMA-11 1enfortumab vedotin 1darolutamide 1Therapeutics 1Radiosurgery 1Radiation Dose Hypofractionation 1Pluvicto 1Mitomycin 1Lutetium-177 1Lutetium 1Loperamide 1Geriatric Assessment 1Gemcitabine 1Fulvestrant 1Fluorouracil 1Fecal Microbiota Transplantation 1Exercise 1Continuous Positive Airway Pressure 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urogenital Neoplasms × Lutetium × 90 days × Clear all
NCT05413850 2026-05-14

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Blue Earth Therapeutics Ltd

Phase 1/2 Recruiting
82 enrolled
Genitourinary

Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡